Skip to content

Posterior cerebraL ArTery Occlusion Study

Endovascular Therapy vs Medical Management of PosterIor Cerebral Artery Occlusion Stroke

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05291637
Acronym
PLATO
Enrollment
1282
Registered
2022-03-22
Start date
2022-01-05
Completion date
2023-01-31
Last updated
2024-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Acute Ischemic

Keywords

Posterior occlusion artery (PCA), Intravenous thrombolysis (IVT), Endovascular therapy (EVT), Modified Rankin Scale (mRS)

Brief summary

For this retrospective study, the investigators will collect and analyze data of patients who presented with posterior artery occlusion and underwent mechanical thrombectomy (the type of endovascular stroke treatment) and intravenous thrombolysis (the type of non-endovascular stroke treatment). The electronic health records will be queried for the demographic, medical history, and outcomes data of all patients with posterior cerebral artery occlusion who underwent mechanical thrombectomy, intravenous thrombolysis (IVT), or medical management.

Detailed description

The primary aims of the research are to evaluate, in patients presenting with posterior artery occlusion (PCA), whether favorable outcome would be superior for EVT compared to Medically Management (MM), inclusive of intravenous thrombolysis (IVT), as measured by: * 90-day modified Rankin Scale (mRS) ordinal shift or * decrease in NIH Stroke Scale/Score (NIHSS) by two points at 24 hours or at hospital discharge The secondary aims are to evaluate in patients presenting with PCA occlusion, other outcome and safety metrics: * 90-day functional independence, mRS 0-2 * 90-day excellent outcome, mRS 0-1 * Visual field recovery (none, partial, complete) by 90-days * rate of reperfusion by modified thrombolysis in cerebral infarction (TICI) scale grade * any intracranial hemorrhage * symptomatic intracranial hemorrhage * mortality In subgroup analysis, the investigators aim to identify subgroups that may confer differential treatment benefit by: * location of occlusion on the PCA segment (P1, P2, P3) * NIHSS strata (0-6, 7-15,\>16) * time from symptom onset to treatment (0 to \<6h vs 6-24h) * posterior circulation (PC) Acute Stroke Prognosis Early Computed Tomography Score (ASPECTS) * visual field defect on presentation The investigators hypothesize that greater benefit in outcomes would be seen in EVT treated patients with higher NIHSS, more proximal PCA occlusion, higher PC ASPECTS scores, and shorter time from symptom onset to treatment.

Interventions

None listed

Sponsors

Heidelberg University
CollaboratorOTHER
Boston Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Had an ischemic stroke with isolated posterior cerebral artery occlusion (P1, P2, or P3 segments) and was medically managed or managed with EVT during the study time period.

Exclusion criteria

* Patient with documented basilar artery occlusion and concomitant PCA occlusion * Patient with documented basilar artery occlusion, migration with secondary PCA occlusion

Design outcomes

Primary

MeasureTime frameDescription
Change in stroke outcome based on modified Rankin Scale (mRS)baseline, 90 daysThe Modified Rankin Scale (mRS) assesses disability in patients who have suffered a stroke and is compared over time to check for recovery and degree of continued disability. Scores can range from 0-6, where 0 is no disability, 5 is disability requiring constant care for all needs, and 6 is death. For this outcome an ordinal shift analysis will be done, assessing all changes across the range from baseline at 90 days.
Change in NIH Stroke Score (NIHSS)baseline, 7 daysThe NIH Stroke Scale/Score (NIHSS) is is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Scores can range from 0 to 42 and higher scores are associated with more severe stroke: 1-4= Minor stroke, 5-15= Moderate stroke, 15-20= Moderate/severe stroke, and 21-42 =Severe stroke.

Countries

Finland, Germany, Italy, Portugal, Spain, Switzerland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026